19:33 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Cell culture and mouse studies suggest promoting CTNNB1 citrullination or PAD2 expression could help treat colorectal cancer. Screening of approved drugs in HEK cell-based assays of CTNNB1 signaling and cell line-based citrullination and...
18:08 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Patient sample, cell culture and mouse studies suggest inhibiting PAD2 could help treat castration-resistant prostate cancer (CRPC). In patient samples, levels of PAD2 were higher in CRPC tumors than in hormone-dependent tumors. In...
07:00 , Jul 9, 2015 |  BC Innovations  |  Product R&D

Downstream without a NET

ModiQuest B.V. has discovered that its therapeutic mAb against citrullinated histones has the potential to treat autoimmune diseases by inhibiting the formation of neutrophil extracellular traps that play a role in the pathogenesis of autoimmunity....
07:00 , Apr 30, 2015 |  BC Innovations  |  Strategy

Padlock's keys to academia

Padlock Therapeutics Inc. isn't using its $23 million from a recent series A round to build research in-house or through a network of CROs. Instead, it's turning to academia to build the biology around its...
08:00 , Jan 19, 2015 |  BioCentury  |  Emerging Company Profile

Unlocking PADs

Padlock Therapeutics Inc. is developing a pipeline of small molecule inhibitors of PAD enzymes to prevent the production of autoantigens that can trigger autoimmune diseases. The approach could selectively treat and potentially even prevent diseases...